Notably, although approximately 50% of patients with CRC harbor RAS mutations (KRAS: 36% and NRAS: 3%) [66], not all patients with KRAS mutations are resistant to EGFR-targeted therapy [67]. This evidence concerns the gene KRAS and colorectal carcinoma.